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ANOVA - analysis of variance  
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CPX - cardiopulmonary exercise testing  
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ICD - International Classification of Diseases  
 
MET – metabolic equivalent 
 
NDI - National Death Index  
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Abstract 
Background: The relationship between cardiorespiratory fitness (CRF) and mortality risk has 
typically been assessed using a single measurement, though some evidence suggests the change 
in CRF over time influences risk. This evidence is predominantly based on studies using 
estimated CRF (CRFe).  The strength of this relationship using change in directly measured CRF 
over time in apparently healthy men and women is not well understood.  Purpose: To examine 
the association of change in CRF over time, measured using cardiopulmonary exercise testing 
(CPX), with all-cause and disease-specific mortality and to compare baseline and subsequent 
CRF measurements as predictors of all-cause mortality. Methods: Participants included 833 
apparently healthy men and women (42.9 ± 10.8 years) who underwent two maximal CPXs, the 
second CPX being ≥ 1 year following the baseline assessment (mean 8.6 years, range 1.0 to 40.3 
years). Participants were followed for up to 17.7 (SD 11.8) years for all-cause-, cardiovascular 
disease- (CVD), and cancer mortality. Cox-proportional hazard models were performed to 
determine the association between the change in CRF, computed as visit 1 (CPX1) peak oxygen 
consumption (VO2peak [mL·kg
-1·
min
-1
]) – visit 2 (CPX2) VO2peak, and mortality outcomes. A 
Wald-Chi square test of equality was used to compare the strength of CPX1 to CPX2 VO2peak in 
predicting mortality. Results: During follow-up, 172 participants died. Overall, the change in 
CPX-CRF was inversely related to all-cause, CVD, and cancer mortality (p<0.05). Each 1 
mL·kg
-1·
min
-1
 increase was associated with a ~ 11, 15, and 16% (all p<0.001) reduction in all-
cause, CVD, and cancer mortality, respectively. The inverse relationship between CRF and all-
cause mortality was significant (p<0.05) when men and women were examined independently, 
after adjusting for years since first CPX, baseline VO2peak, and age. Further, the Wald Chi-square 
test of equality found CPX2 VO2peak to be a significantly stronger predictor of all-cause mortality 
than CPX1 VO2peak (p<0.05). Conclusion: The change in CRF over time was inversely related to 
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mortality outcomes, and mortality was better predicted by CRF measured at subsequent test than 
CPX1 CRF. These findings emphasize the importance of adopting lifestyle behaviors that 
promote CRF, as well as support the need for routine assessment of CRF in clinical practice to 
better assess risk.  
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Introduction 
Healthy lifestyles are gaining increased recognition in clinical and public health settings.
1, 
2
 Cardiorespiratory fitness (CRF) is a key outcome measure associated with healthy lifestyles. 
Evidence has consistently shown CRF to be a strong and independent predictor of chronic 
disease, including CVD, cancer, and all-cause mortality.
3-7
 Several studies have shown CRF to 
be a better predictor of health outcomes in both healthy and clinical populations than traditional 
cardiovascular disease (CVD) risk factors that are commonly assessed clinically.
4, 5
  
CRF is a modifiable risk factor that is influenced by lifestyle and health parameters, 
including exercise training status.
8-11
  Improvements in CRF have been shown to result in 
beneficial changes in traditional risk factors and health.
12-14
 Additionally, there is growing 
evidence suggesting changes in estimated CRF (CRFe) over time (>1 year), are associated with 
changes in mortality risk.
15-21
 Since CRF may change over time, the routine assessment of CRF 
may have stronger prognostic value and use as a mortality risk assessment tool than a single CRF 
measurement.  
Past studies assessing the association between the change in CRF over time and mortality 
have predominately used CRFe from exercise test workload or duration.
4, 15-17, 19-21
 Additionally, 
past studies have only assessed men and used cohort specific reference values to define CRF 
thresholds.
4, 15-17, 19, 21
 These factors may limit the generalizability of the findings and clear  
understanding of this relationship.
22, 23
 Further, the estimation errors associated with CRFe may 
impact an individual’s risk assessment, reducing its sensitivity.  
Recent scientific statements and reviews have emphasized the need for more studies 
assessing the association between directly measured CRF, obtained from cardiopulmonary 
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exercise testing (CPX-CRF) which is considered the gold standard method, and mortality 
outcomes.
24, 25
 Only two studies have used CPX-CRF as a baseline measure and only one study 
has examined the association between the change in CPX-CRF and mortality apparently healthy 
individuals.
3, 15
 Laukkanen et al studied 579 men (age range: 42-60 y) from eastern Finland who 
performed two CPX with cycle ergometry 11-years apart.
15
  After a median follow-up of 13.3 
years from the second CPX, a graded relationship was found, where each 1 MET higher change 
was associated with a 30% lower risk of all-cause mortality. The findings from this study of 
middle-aged Finnish men tested using a cycle ergometer protocol may not be generalizable to 
other populations, including women, nor to CPX-CRF measured using treadmill as the mode for 
testing. Therefore, the primary aim of this study was to examine the association of the change in 
CPX-CRF over time (>1 year between CRF measures) with all-cause and disease-specific 
mortality in a cohort of apparently healthy men and women. Secondly, this study sought to 
determine if a second measure of CRF, > 1 year after the first, improves the prediction of 
mortality risk across time above a single measure. 
Methods 
The study cohort included 833 apparently healthy participants (552 men, 281 women; 
baseline mean age: 42.9 ± 10.8, range 18.0 - 82.0 years) obtained from the Ball State Adult 
fitness Longitudinal Lifestyle STudy (BALL ST) cohort. Participants were self-referred either to 
the Ball State University-Adult Physical Fitness Program, a community-based exercise program 
or were research subjects in clinical exercise physiology related studies who gave written 
informed consent for their data to be used for research. Participants were considered apparently 
healthy, as all were free from known CVD (history of cardiac arrest, coronary artery disease, 
heart failure, myocardial infarction, and stroke) and cancer at baseline or follow-up. CVD 
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diagnosis was self-reported and verified by written physician confirmation. All participants 
completed two health and fitness assessments between 1969 and 2017, each including a CPX 
achieving a peak effort criteria of a respiratory exchange ratio ≥1.0 during both CPX1 and 
CPX2. These two exams were ≥ 1 year apart (mean 8.6 years, range 1.0 to 40.3years). This study 
was reviewed by the Ball State University Institutional Review Board and determined exempt as 
only de-identified data were used. 
Resting Health Assessment 
A full description of the procedures involved in the resting health and fitness 
measurements performed prior to both CPXs have been explained previously.
26, 27
 In summary, 
participants completed a health history questionnaire, providing demographic information, 
personal and family medical history, medication usage, and lifestyle behaviors. Information 
gained from the questionnaire was used to screen for medical contraindications and/or physical 
limitations to CPX.  
Lifestyle behaviors of physical activity (PA) and smoking were self-reported. PA status 
was classified as inactive or active, with active being designated if participants reported 
engagement in regular PA, meeting the US aerobic PA guidelines for adults.
28
  Smoking status 
was categorized as current smoker, including those that used cigarettes or quit within the past 
year, or a non-smoker at CPX1.   
Clinical measurements including, resting heart rate, blood pressure, anthropometrics 
(height, weight, waist circumference), 12-lead electrocardiogram, and blood chemistry (≥ 8 hour 
post-prandial), were performed by trained technicians using standardized laboratory procedures. 
These measurements were used to determine the presence of risk factors, including obesity, 
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hypertension, dyslipidemia, and impaired fasting glucose, defined according to current accepted 
atherosclerotic CVD risk factor criteria.
29
     
Assessment of CRF 
A more thorough description of the procedures used to assess CRF have been described 
previously.
3, 26
 In summary, at visit one CPX was performed using a standardized treadmill or 
cycle protocol, to determine peak oxygen consumption (VO2peak). The mode of exercise was 
chosen based on participant preference, comfort, and the presence of functional limitations as 
determined through the health history questionnaire. Standardized procedures were followed for 
metabolic cart calibration and all CPXs were supervised by trained clinical exercise 
physiologists, with additional medical supervision when appropriate.
30
 Participants were 
encouraged to exercise to volitional fatigue and a respiratory exchange ratio ≥ 1.0 was used as an 
objective indicator of maximal effort.  
All participants were re-tested in the Clinical Exercise Physiology laboratory ≥ 1 year 
after their baseline assessment. At this second assessment, both CPX-CRF and resting health and 
fitness measurements were reassessed following the same standardized procedures and criteria as 
at baseline. CPX2 was also performed using the same mode of exercise as at CPX1. 
Outcomes and Follow-up 
All participants were followed from the date of their CPX2 through 2017 or until date of 
death for all-cause mortality or December 31, 2016 for disease-specific mortality. The National 
Death Index (NDI) was the primary data source for obtaining vital status between 1979 and 
2016, providing date of death and cause of death. There were no deaths reported in the cohort 
prior to 1979. Deaths occurring after 2016 (n=10) were confirmed by obituary review.  The 
underlying cause of death determined from the NDI report was coded according to the 
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International Classification of Diseases (ICD), 9
th
 revision, prior to 1999 and the ICD, 10
th
 
revision, from 1999 to 2016.
31, 32
 CVD mortality was defined by the ICD, 9
th
 revision codes 
390.0 to 449.9 and ICD, 10
th
 revision codes I00.0 to I78.9. Cancer mortality was defined by the 
ICD, 9
th
 revision codes 140.0 to 239.0 and ICD, 10
th
 revision codes C00.0 to D49.9. For all other 
ICD codes, cause of death was classified as other. 
Statistical analysis 
SPSS V. 24 (SPSS, Inc., Chicago, IL) and SAS V. 9.3, were used for all statistical 
analyses. Descriptive statistics were performed to summarize characteristics of the cohort and a 
univariate analysis of variance (ANOVA) and chi-square goodness of fit test were used when 
appropriate to test for significant differences between sexes and vital status (living vs. deceased). 
Paired T-tests were used to assess the differences between resting health and fitness and CPX 
measurements. To determine significant differences between CPX1 and CPX2 measures, all 
descriptive data were normalized to account for differences in the number of years between 
subject’s CPXs. Cox proportional hazard models were used to determine hazard ratios (HR) and 
95% confidence intervals (CI) associated with the change in CRF as related to all-cause, CVD, 
and cancer mortality.  Sex-specific hazard models were used to determine the HR related to all-
cause mortality according to change in CRF. There were an inadequate number of cases of CVD 
and cancer specific mortality for sex-specific analyses. CRF was expressed as VO2peak in mL·kg
-
1·
min
-1
 and the continuous change in CRF was computed as the difference in VO2peak between 
CPX1 and CPX2. The Cox proportional hazard models were fit to the data and run adjusted for 
years between CPXs (model 1), additionally controlled for CPX1 VO2peak, age, and sex (model 
2), and then with further adjustment for the change in traditional CVD risk factors (model 3; 
dyslipidemia, hypertension, impaired fasting glucose, obesity, physical inactivity and smoking 
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status), which were categorized by the change in each risk factor status between CPX1 and 
CPX2. The Cox models were obtained separately on a sub-group of the cohort with ≥ 5 years 
(n=491) between CPXs to determine if the relationship remained consistent. A Wald Chi-square 
test was used to compare the coefficients estimating the relationship of CPX1 CRF to CPX2 
CRF with time until death for all-cause mortality. These models were obtained both unadjusted, 
and then adjusted for years between CPXs, age, and sex. 
Results 
Table 1 provides descriptive characteristics of the study cohort at CPX1.  Men had a 
higher absolute CRF than women, however, there were no differences in their values based on 
age and sex specific reference standards. Additionally, men had a less favorable risk factor 
profile with a higher prevalence of dyslipidemia, impaired fasting glucose, hypertension, 
physical inactivity, and smoking (p<0.05).  
During the follow-up period (17.7 ± 11.8 years, range: 1.0 - 45.8 years) 172 participants 
died (132 men, 40 women), with an overall incidence rate of 11.6 deaths per 1,000 person years.  
The mean age difference for the entire cohort between CPX1 and CPX2 was 8.5 years and the 
mean change in CRF was -1.8 mL·kg
-1·
min
-1
. Table 2 provides a comparison of the descriptive 
characteristics at CPX1 for participants identified as living and deceased at time of follow-up. 
Overall, at CPX1 participants that died during the follow-up period were older, more likely to be 
obese, physically inactive, and have dyslipidemia (p<0.05). Additionally, at CPX1 women that 
died during the follow-up period had a significantly higher prevalence of hypertension, but were 
less likely to have diabetes, and men were more likely to be smokers than their living 
counterparts (p<0.05).   
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Results from the Cox proportional hazard models assessing risk for all-cause, CVD, and 
cancer mortality according to per unit change in VO2peak (mL·kg
-1·
min
-1
) between CPX1 and 
CPX2 are shown in Table 3a. Overall, there was an inverse relationship between the change in 
CRF and risk for all-cause, CVD, and cancer mortality after adjusting for years between CPXs 
(model 1). After further adjustment for baseline VO2peak, age, and sex (model 2), the strength of 
the association was increased. The inverse association found between the change in CRF and all-
cause (p<0.01) and disease-specific mortality (p<0.05) outcomes remained significant in the 
multivariable adjusted model (model 3). Specifically, a 1 mL·kg
-1·
min
-1 
increase was found to be 
associated with ~11%, 15%, and 16% lower risk of all-cause, CVD, and cancer mortality, 
respectively (p<0.001).  The inverse relationship between the change in CRF expressed as 
absolute VO2peak (L·min
1
) and risk for all-cause, CVD, and cancer mortality was significant 
(p<0.05) for each model.  
The inverse association between change in VO2peak and all-cause mortality was also 
present for both men and women, when assessed independently, in both models 1 and 2 (Table 
3b). Specifically in model 2, a 1 mL·kg
-1·
min
-1 
increase was found to be associated with 
approximately a 10% and 11% lower risk of all-cause mortality in men and women, respectively 
(p<0.05). In model 3, following multivariable adjustment the strength of the association 
remained for men with a 11% lower all-cause mortality risk per 1 mL·kg
-1·
min
-1
 in VO2peak. 
However, in women, the relationship was attenuated and no longer significant in model 3 
(p=0.29).  
To assess if the relationship remained consistent when assessing the change in CRF over 
a longer period of time between CPXs, Cox models were obtained on a sub-group with ≥ 5 years 
between CPX1 and CPX2. The inverse association between the change in CRF and all-cause, 
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CVD, and cancer mortality was also significant in this sub-cohort (n=491, 104 deceased) in both 
model 1 (HR=0.956, 95% CI=0.929 - 0.983; HR=0.938, 95% CI=0.890 - 0.988; HR=0.954, 95% 
CI=0.906 - 0.998, respectively) and in model 2 (HR=0.931, 95% CI=0.897 - 0.967; HR=0.923, 
95% CI=0.861 - 0.990; HR=0.925, 95% CI=0.864 - 0.990, respectively). Model 3 showed each 1 
ml·kg
-1
·min
1 
increase in CRF to be significantly associated with 6% lower risk of all-cause 
mortality (p<0.01), and to be marginally associated with an 8.7% and 7.2% lower risk for CVD 
(p=0.09) and cancer mortality (p=0.10), respectively.  
Results from the Cox proportional hazard model and Wald-chi square test of equality 
comparing CPX1 CRF to CPX2 CRF as predictors for all-cause mortality are shown in Table 4. 
CRF measured at CPX2 was found to be a stronger predictor of all-cause mortality than the 
CPX1 CRF measurement in the unadjusted model, as well as after adjusting for years between 
CPXs, VO2peak measured at CPX1, age, and sex.  
Discussion 
The change in CPX-derived CRF over time in apparently healthy adults was found to be 
a strong predictor of all-cause, CVD, and cancer mortality. Significant changes in mortality 
outcomes were seen even with small changes in CRF (1 mL·kg
-1·
min
-1
) and were independent of 
changes in traditional CVD risk factors. These results highlight the importance of improving low 
CRF or maintaining an adequate CRF level throughout the lifespan for both men and women.  
 The inverse relationship found in the current study using CPX-CRF revealed a stronger 
association with mortality compared to past studies that used CRFe. Overall, the current study 
found a 37.8% lower risk in all-cause mortality risk with each MET higher change (10.8% lower 
risk per 1 mL·kg
-1·
min
-1
; 1 MET =
 
3.5 ml·kg
-1·
min
-1
), and risk reductions of 35.4% and 27.3% 
per 1 MET increase in men and women when assessed independently. To place this change in 
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perspective, each decade of age is associated with >1 MET reduction in CRF.  Blair et al. studied 
9,777 men from the Aerobic Center Longitudinal Study cohort who performed two preventative 
maximal exercise tests that were approximately 5 years apart, using CRFe.
18
 Results showed a 
16% reduction in all-cause mortality risk per 1 MET improvement. More recently, Shah et al 
assessed this relationship in 4,872 young adults (54% women, mean age 24.8 y) that performed 
two exercise tests, approximately 7 years after baseline.
20
 After approximately 20 years of 
follow-up, results showed that for every one minute reduction in exercise time on the modified 
Balke protocol (each minute on the exercise test is approximately equal to 1 MET) there was a 
21% increase in all-cause mortality. Although differences in the strength of the association 
between the current study findings and those from these past studies may result from differences 
in cohort characteristics, the method used to measure CRF may have also impacted the findings.
9
  
A common limitation of CRFe, is the reported estimation error of approximately ± 1 to 2 
METs.
9, 29, 33, 34
 Given that exercise training can result in CRF improvements of this amount,
35
 
this error may lead to erroneous interpretation of one’s change in CRF level (i.e. fit to fit vs. unfit 
to fit), limiting the strength of the association. These limitations may be overcome by CPX, 
which provides a direct, quantitative, and more accurate measure of CRF.
22, 23, 36
 However, only 
one other study to date has assessed the relationship between the change in CPX-CRF over time 
(>1 year) and mortality risk in apparently healthy individuals.
15
 This study assessed middle aged 
men (42 - 60 years) from eastern Finland that performed two CPXs using cycle ergometry with 
11 years between tests. Results showed each 1 ml·kg
-1·
min
-1 
increase in CPX-CRF was 
associated with a 10% lower risk of all-cause mortality after adjusting for baseline VO2peak. The 
current results showed similar findings, of an 11.1% and 9.7% lower risk for all-cause mortality 
per 1 mL·kg
-1·
min
-1 
increase in VO2peak in the overall cohort and in men only, after similar model 
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adjustment, respectively. However, CRF is known to be influenced by sex and age.
22, 36-38
 We 
also observed a 11.3% lower risk for all-cause mortality per 1 mL·kg
-1·
min
-1 
increase in VO2peak 
in the women. The wider age distribution, use of treadmill as a mode with CPX, and the 
inclusion of women in the current cohort, helps to advance our understanding of the influence 
CPX-CRF has on mortality outcomes across the lifespan.  
 There was also a significant inverse relationship found between the change in CRF and 
disease-specific mortality in the current cohort. Each 1 mL·kg
-1·
min
-1 
increase was associated 
with ~15% and 16% lower risk of CVD and cancer mortality, respectively, both corresponding to 
>50% lower risk per 1 MET increase. Lee et al assessed the change in CRFe, as related to CVD 
mortality in a cohort of ~14,000 men from the ACLS cohort that performed two exercise tests.
17
 
Results showed each 1 MET improvement was associated with a 19% reduction in CVD 
mortality.  Zhang et al also assessed men of the ACLS cohort, examining the relationship 
between the change in CRFe and cancer mortality.
16
 Results showed a 5% lower risk of cancer 
mortality with each 1 MET increase. Discrepancies in the findings between studies may be due 
to differences in cohort characteristics, the time period between tests, as well as methodological 
factors such as the different methods used in determining CRF. 
 A recent 2016 AHA scientific statement advocated that CRF should be considered a 
clinical vital sign.
9
 The findings from the current study demonstrate the value of periodic 
measurement of CPX-CRF as the change in CPX-CRF over time was found to improve mortality 
risk assessment compared to one-time measure. In a cross-sectional analysis using the current 
cohort assessing the relationship between baseline CPX-CRF and all-cause mortality, there was 
an 11.6% lower risk per MET increment difference, which was similar to the 13% lower risk of 
all-cause mortality per MET increment difference reported in a review by Kodama et al of 33 
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studies assessing the cross-sectional relationship between CRF and mortality.
3, 7
 However, the 
magnitude of the association between the change in CRF and all-cause mortality was found to be 
greater than that found using a single measure, with a nearly 27% lower risk per MET increase 
between CPX1 and CPX2. The smaller magnitude of the association found in these cross-
sectional analyses may be a result of the lack of information on changes in CRF over time, 
especially since an expected response to identification of low CRF would be to begin or increase 
exercise training.  To further highlight the importance of routine CRF assessment, CRF measures 
taken at CPX1 and CPX2 were compared as predictors of mortality. The CPX2 CRF was found 
to be a stronger predictor of all-cause mortality compared with the CPX1 CRF measure.  
On average, CRF declines at least 1 MET per decade of age
22, 39
 and the current study suggests 
that attenuating this decline is associated with reduced risk of mortality.  Regular PA can help 
mitigate this age-related reduction to preserve an adequate/acceptable CRF level for one’s age 
and sex. PA behavior accounts for approximately 50% of the variation in CRF and it has been 
reported that individuals beginning a moderate to vigorous aerobic exercise program can increase 
their CRF by approximately 1 to 2 METs.
8, 35, 40
 On the contrary, those that reduce their PA over 
time can experience lifestyle related declines in CRF, greater than  normally experienced due to 
increasing age.
41
 These changes in PA behavior, influencing changes in CRF may potentially 
alter mortality risk over time. These results can be seen as encouraging for individuals that have 
low CRF, as they suggest CRF improvements, achievable through regular PA/exercise, can 
reduce mortality risk.   
Strengths and Limitations 
The study used CPX, the gold standard method for measuring CRF, providing an 
accurate representation of the change in CRF over time. Additionally, the BALL ST cohort 
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consisted of men and women across a wide distribution of age and risk factors. Therefore, the 
results may be more representative of the population that clinicians see on a regular basis, 
enhancing utilization in clinical practice. Sex-specific analyses were also performed when 
assessing all-cause mortality, compared to most studies including both men and women, which 
have solely adjusted for sex in statistical models. This cohort allows for a better understanding of 
how changes in CPX-CRF may influence prognosis differently in men and women. Finally, the 
study had an extensive mortality follow-up of 17.7 years, which adds to the knowledge base of 
the impact changes in CRF across time have on mortality risk. 
The limitations of the present study include a > 90% non-Hispanic white cohort. Future 
work is needed to confirm these findings in populations from diverse racial and ethnic 
backgrounds that are known to influence health outcomes.
42
 Additionally, statistical power was 
reduced for sex-specific analyses when assessing disease-specific mortality, therefore men and 
women were only analyzed independently when assessing all-cause mortality outcomes. Future 
studies should assess the association between the change in CRF and CVD and cancer-specific 
mortality in a large cohort of men and women with greater disease-specific mortality end-points.  
Conclusion 
 Change in CPX-CRF over time was inversely related to all-cause, CVD, and cancer 
mortality in a cohort of apparently healthy adults. This relationship was strengthened when 
accounting for the change in traditional CVD risk factors, further demonstrating the importance 
of CRF for determining health outcomes.  These findings support the clinical value of CPX-CRF 
and highlight the importance of its routine measurement in clinical practice. Although clinicians 
should encourage all to participate in regular PA/exercise, as a way to help improve or maintain 
adequate CRF levels, these findings may be particularly promising to those identified as low fit, 
as they suggest even small improvements in CRF can have a profoundly positive impact on 
reducing mortality risk.  
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Table 1.  Descriptive characteristics of the BALL ST Cohort at CPX1 
 Men (n=552) Women (n=281) 
Age (years) 44.6 ± 9.8 45.0 ± 10.8 
VO2peak (mL·kg
-1·
min
-1
) 36.6 ± 9.3
*
 27.8 ± 7.3 
VO2peak (L·min
-1
) 3.10 ± 0.03
*
 1.90 ± 0.04 
METs 10.8 ± 2.7
*
 8.3 ± 2.2 
FRIEND percentile
7,8 
46 ± 26 54±25 
Weight (kg) 87.2± 16.8
*
 69.5± 14.6 
BMI (kg·m
-2
) 27.2 ± 4.7 26.0± 5.7 
Waist (cm) 84.5±32.1 80.1±12.8 
Blood glucose (mg·dL
-1
) 98.1±28.5
*
 94.0±19.3 
Total cholesterol (mg·dL
-1
) 212.1±46.2 202.2± 39.2 
SBP/DBP (mmHg)
 
126
*
/81
*
± 13/9 119/76 ± 16/11 
RHR (bpm) 68 ± 13 72 ± 11 
HRmax (bpm) 176 ± 16 177 ± 14 
Risk Factors   
Obesity (%) 22 24 
Impaired fasting glucose (%) 31 26 
Dyslipidemia (%)
 
61
*
 36 
Hypertension (%)
 
32
*
 21 
Physical inactivity (%)
 
62
*
 77 
Smoking (%) 12
*
 6 
 
Abbreviations:  BALL ST, Ball State Adult fitness program Longitudinal Lifestyle STudy 
(BALL ST) cohort; BMI, body mass index; DBP, diastolic blood pressure; FRIEND, Fitness 
Registry and the Importance of Exercise National Database; HRmax, maximal heart rate; METs, 
metabolic equivalents; RHR, resting heart rate; SBP, systolic blood pressure; VO2peak, peak 
oxygen consumption.  Prevalence of obesity, impaired fasting glucose, dyslipidemia, 
hypertension, and physical inactivity was defined per current accepted atherosclerotic CVD risk 
factor criteria.
29
   
*
p≤ 0.05  
Data are expressed as mean ± SD or %. 
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Table 2. Descriptive Characteristics at CPX1 of the Living and Deceased participants 
within the BALL ST cohort 
 Men Women 
Living (n=420) Deceased (n=132) Living (n=241) Deceased (n=40) 
Age (years) 42.8 ± 9.8
*
 49.3 ± 8.7 43.1 ± 10.4
*
 51.8 ± 12.0 
RHR (bpm) 69 ± 13 64 ± 16 72 ± 11 71 ± 11 
HRmax (bpm) 178 ± 16 173 ± 16 179 ± 13
*
 169 ± 19 
VO2peak 
 (mL·kg
-1·
min
-1
) 
37.2 ± 9.6
* 
34.1 ± 8.3 28.4 ± 7.6 27.2 ± 6.9 
VO2peak (L·min
-1
) 3.19 ± 0.66
*
 2.80 ± 0.65 1.92 ± 0.42 1.83 ± 0.46 
METs 10.7 ± 2.7
*
 9.7 ± 2.2 8.1 ± 2.2 7.8 ± 2.0 
FRIEND percentile
7,8 
47 ± 27 44 ± 24 54 ± 25 57 ± 25 
Weight (kg) 87.6 ± 17.2
* 
83.7 ± 14.0 69.2 ± 14.4 68.0 ± 15.1 
BMI (kg·m
-2
) 27.4 ± 4.8 26.3 ± 3.9 25.7 ± 5.6 25.9 ± 5.8 
Waist (cm) 94.8 ± 12.6 93.3 ± 9.0 79.9 ±12.6 79. 5± 14.3 
Blood glucose 
(mg·dL
-1
) 
97.8 ± 28.0 95.3 ± 25.7 93.7 ± 21.0 94.8 ± 11.5 
Total cholesterol 
(mg·dL
-1
) 
207.3 ± 45.2
*
 228.5 ± 45.7 199.7 ± 38.9
*
 217.3 ± 37.8 
SBP/DBP (mmHg) 125
*
/81 ± 13/9 129/83 ± 12/9 118
*
/76
*
± 14/10 127/80 ± 19/12 
Risk Factors     
Obesity  (%) 25
*
 12 24
*
 20 
Diabetes (%) 31 35 27
*
 22 
Dyslipidemia (%) 59
*
 68 34
*
 45 
Hypertension (%) 32 32 20
*
 30 
Physical inactivity 
(%) 
59
*
 68 75
*
 85 
Smoking (%) 11
*
 16 5 6 
Abbreviations:  BALL ST, Ball State Adult Fitness Program Longitudinal Lifestyle STudy 
(BALL ST) cohort; BMI, body mass index; CPX, cardiopulmonary exercise testing; DBP, 
diastolic blood pressure; FRIEND, Fitness Registry and the Importance of Exercise National 
Database; HRmax, maximal heart rate; METs, metabolic equivalents; RHR, resting heart rate; 
SBP, systolic blood pressure; VO2peak, peak oxygen consumption. Prevalence of obesity, 
impaired fasting glucose, dyslipidemia, hypertension, and physical inactivity was defined per 
current accepted atherosclerotic CVD risk factor criteria.
29
   
*
 p≤0.05, living vs. deceased  
Data are expressed as mean ± SD or %. 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
 
Table 3a.  Hazard ratios for all-cause, CVD, and cancer mortality outcomes for BALL-ST 
cohort according to change in CRF, expressed as both VO2peak and METs. 
Mortality Hazard Ratio (95% CI) % reduction/ 
mL·kg
-1·
min
-1 
 
% reduction / 
MET  
All-cause mortality 
Model 1  0.923
*
 (0.953 – 0.972) 7.7 27.0 
Model 2 0.889
*
 (0.873 – 0.926) 11.1 38.9 
Model 3 0.892
*
 (0.843 – 0.943) 10.8 37.8 
CVD mortality  
Model 1  0.900
*
 (0.863 – 0.939) 10.0 35.0 
Model 2 0.886
*
 (0.840 – 0.935) 11.4 39.9 
Model 3 0.853✝ (0.750 – 0.971) 14.7 51.5 
Cancer mortality  
Model 1  0.924✝
 
(0.887 – 0.962) 7.6 26.6 
Model 2 0.894
*
 (0.849 – 0.942) 10.6 27.1 
Model 3 0.861
* 
(0.774 – 0.957) 15.9 55.7 
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Table 3b.  Hazard ratios for all-cause mortality outcomes for men and women according to 
change in CRF, expressed as both VO2peak and METs. 
All-cause mortality  Hazard Ratio (95% CI) % reduction/ 
ml·kg
-1·
min
-1
  
% reduction/ 
MET  
Men 
Model 1 0.934
*
 (0.911 – 0.957) 6.6 23.1 
Model 2 0.903
*
 (0.874 – 0.933) 9.7 34.0 
Model 3 0.899
*
 (0.842 – 0.960) 10.1 35.4 
Women 
Model 1 0.897
*
 (0.929 – 0.999) 10.3 36.1 
Model 2 0.887
*
 (0.825 – 0.953) 11.3 39.6 
Model 3 0.922 (0.793 – 1.072) 7.8 27.3 
Abbreviations: CRF=cardiorespiratory fitness; CVD=cardiovascular disease; VO2peak= peak 
oxygen consumption. 
*
p≤0.01 
✝p≤0.05 
Model 1 adjusted for years since first CPX; Model 2 adjusted for years since first CPX, CPX1 
VO2peak, and age in the sex-specific analyses with the addition of sex in the overall sample; 
Model 3 adjusted for years since first CPX, CPX1  VO2peak, age, examination year, and change in 
risk factors (dyslipidemia, hypertension, impaired fasting glucose, obesity, physical inactivity, 
and smoking) for the sex-specific analyses with the addition of sex when models were obtained 
for the overall sample. 
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Table 4. Absolute parameter estimates comparing the relationship between CPX1 VO2peak 
and CPX2 VO2peak in the cox model to mortality outcomes with Wald Chi-square test of 
equality. 
 Absolute parameter 
estimate CPX1 
Absolute parameter 
estimate CPX2
 
p 
Model 1 0.014 0.052
*
 0.001 
Model 2 0.006 0.029
*
 0.001 
Abbreviations:  CPX, cardiopulmonary exercise testing; VO2peak, peak oxygen consumption 
*
Comparison of the coefficients for CPX1 VO2peak to VO2peak measured at CPX2. 
Model 1 run unadjusted; Model 2 adjusted for years since first CPX, CPX1 VO2peak, age, and 
sex. 
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